Howard Mackey

4.1k total citations · 3 hit papers
22 papers, 2.8k citations indexed

About

Howard Mackey is a scholar working on Molecular Biology, Oncology and Statistics and Probability. According to data from OpenAlex, Howard Mackey has authored 22 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Statistics and Probability. Recurrent topics in Howard Mackey's work include Hedgehog Signaling Pathway Studies (8 papers), Alzheimer's disease research and treatments (4 papers) and Statistical Methods in Clinical Trials (4 papers). Howard Mackey is often cited by papers focused on Hedgehog Signaling Pathway Studies (8 papers), Alzheimer's disease research and treatments (4 papers) and Statistical Methods in Clinical Trials (4 papers). Howard Mackey collaborates with scholars based in United States, United Kingdom and Switzerland. Howard Mackey's co-authors include Jennifer A. Low, Robert L. Yauch, Charles M. Rudin, Josina C. Reddy, Richard Graham, Deborah K. Armstrong, Richard T. Penson, Robert M. Wenham, Robert A. Burger and Mitesh J. Borad and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Howard Mackey

21 papers receiving 2.7k citations

Hit Papers

Efficacy and Safety of Vismodegib in Advanced Basal-Cell ... 2007 2026 2013 2019 2012 2009 2007 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
    2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine profile →
  2. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
    2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. New England Journal of Medicine profile →
  3. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
    2007 574 citations Richard T. Penson, Howard Mackey et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Howard Mackey United States 11 1.9k 885 699 621 474 22 2.8k
Josep M. Piulats Spain 30 1.1k 0.6× 1.5k 1.7× 303 0.4× 112 0.2× 168 0.4× 162 3.2k
Gian Luigi Taddei Italy 26 595 0.3× 488 0.6× 347 0.5× 83 0.1× 359 0.8× 136 2.3k
Nicolaus Friedrichs Germany 30 1.7k 0.9× 945 1.1× 186 0.3× 167 0.3× 67 0.1× 75 3.3k
Lorenza Pecciarini Italy 17 836 0.4× 860 1.0× 156 0.2× 141 0.2× 76 0.2× 42 2.1k
Josina C. Reddy United States 13 2.6k 1.3× 814 0.9× 803 1.1× 748 1.2× 22 0.0× 18 3.1k
Fujio Kasumi Japan 30 1.4k 0.7× 1.4k 1.6× 156 0.2× 223 0.4× 60 0.1× 122 3.4k
Tony Ng Canada 22 938 0.5× 505 0.6× 211 0.3× 60 0.1× 110 0.2× 57 2.2k
Ji Shin Lee South Korea 27 1.0k 0.5× 600 0.7× 172 0.2× 122 0.2× 43 0.1× 90 1.9k
Kathleen Cieply United States 30 940 0.5× 857 1.0× 111 0.2× 75 0.1× 177 0.4× 58 2.6k
Jordi Xercavins Spain 26 442 0.2× 490 0.6× 326 0.5× 43 0.1× 473 1.0× 86 1.9k

Countries citing papers authored by Howard Mackey

Since Specialization
Citations

This map shows the geographic impact of Howard Mackey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Mackey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Mackey more than expected).

Fields of papers citing papers by Howard Mackey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard Mackey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Mackey. The network helps show where Howard Mackey may publish in the future.

Co-authorship network of co-authors of Howard Mackey

This figure shows the co-authorship network connecting the top 25 collaborators of Howard Mackey. A scholar is included among the top collaborators of Howard Mackey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard Mackey. Howard Mackey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sink, Kaycee M., Jillian Smith, Reina N. Fuji, et al.. (2019). P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 15(7S_Part_4). 2 indexed citations
3.
Sink, Kaycee M., Susanne Ostrowitzki, Helen Lin, et al.. (2019). Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) (P4.1-002). Neurology. 92(15_supplement). 2 indexed citations
4.
Lin, Helen, Susanne Ostrowitzki, Kaycee M. Sink, et al.. (2018). O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD). Alzheimer s & Dementia. 14(7S_Part_4). 2 indexed citations
5.
6.
7.
Boyd, Zachary, Dustin Smith, Brian M. Baker, et al.. (2016). Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab. Cancer Immunology Research. 4(1_Supplement). B001–B001. 9 indexed citations
8.
Nguyen-Nielsen, Mary, Lisa Wang, Lars Pedersen, et al.. (2015). The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010. European Journal of Dermatology. 25(5). 463–468. 22 indexed citations
9.
Mackey, Howard & Thomas Bengtsson. (2013). Sample size and threshold estimation for clinical trials with predictive biomarkers. Contemporary Clinical Trials. 36(2). 664–672. 10 indexed citations
10.
Fridlyand, Jane, Ru‐Fang Yeh, Howard Mackey, et al.. (2013). An industry statistician's perspective on PHC drug development. Contemporary Clinical Trials. 36(2). 624–635. 4 indexed citations
11.
Berlin, Jordan, Johanna C. Bendell, Lowell L. Hart, et al.. (2012). A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Cancer Research. 19(1). 258–267. 143 indexed citations
12.
Sekulić, Aleksandar, Michael R. Migden, Anthony E. Oro, et al.. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 366(23). 2171–2179. 1011 indexed citations breakdown →
13.
Bendell, Johanna C., Lowell L. Hart, Irfan Firdaus, et al.. (2010). Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 28(15_suppl). 3530–3530. 10 indexed citations
14.
Hoff, Daniel D. Von, Patricia LoRusso, Charles M. Rudin, et al.. (2009). Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 361(12). 1164–1172. 833 indexed citations breakdown →
15.
Mackey, Howard, et al.. (2009). Some Notable Properties of the Standard Oncology Phase I Design. Journal of Biopharmaceutical Statistics. 19(3). 543–555. 4 indexed citations
16.
LoRusso, Patricia, Charles M. Rudin, Mitesh J. Borad, et al.. (2008). A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3516–3516. 25 indexed citations
17.
Hoff, Daniel D. Von, Charles M. Rudin, Patricia LoRusso, et al.. (2008). Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients. Cancer Research. 68(9_Supplement). LB–138. 10 indexed citations
18.
Rudin, Charles M., Daniel D. Von Hoff, Patricia LoRusso, et al.. (2008). 355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449. European Journal of Cancer Supplements. 6(12). 112–113. 2 indexed citations
19.
Cannistra, S A, U. Matulonis, Richard T. Penson, et al.. (2006). Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clinical Oncology. 24(18_suppl). 5006–5006. 43 indexed citations
20.
Mackey, Howard, et al.. (1987). Induction of a neural phenotype in a serotonergic endocrine cell derived from the neural crest. Journal of Neuroscience. 7(9). 2874–2883. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josep M. Piulats Breakdown of academic impact, for papers by Gian Luigi Taddei Breakdown of academic impact, for papers by Nicolaus Friedrichs Breakdown of academic impact, for papers by Lorenza Pecciarini Breakdown of academic impact, for papers by Josina C. Reddy Breakdown of academic impact, for papers by Fujio Kasumi Breakdown of academic impact, for papers by Tony Ng Breakdown of academic impact, for papers by Ji Shin Lee Breakdown of academic impact, for papers by Kathleen Cieply Breakdown of academic impact, for papers by Jordi Xercavins
Rankless by CCL
2026